Please use this identifier to cite or link to this item: http://docs.prosentient.com.au/prosentientjspui/handle/1/10310
Title: Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Authors: Talaulikar, Dipti
Tam, Constantine S
Joshua, Douglas
Ho, Joy Phoebe
Szer, Jeff
Quach, Hang
Spencer, Andrew
Harrison, Simon
Mollee, Peter
Roberts, Andrew W
Horvath, Noemi
Lee, Cindy
Zannettino, Andrew
Brown, Ross
Augustson, Bradley
Jaksic, Wilfrid
Gibson, John
Kalff, Anna
Johnston, Anna
Trotman, Judith
Kalro, Akash
Grigoriadis, George
Ward, Chris
Prince, H Miles
Affiliation: Department of Haematology, Canberra Hospital, Canberra, Australian Capital Territory, Australia.. Australian National University, Canberra, Australian Capital Territory, Australia.. Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia..
Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.. Department of Haematology, St Vincent's Hospital, Melbourne, Victoria, Australia.. Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.. Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.. Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.. Department of Clinical Haematology and BMT, Royal Melbourne Hospital, Melbourne, Victoria, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, St Vincent's Hospital, Melbourne, Victoria, Australia.. Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.. Department of Haematology, The Alfred Hospital, Melbourne, Victoria, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.. Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.. School of Medicine, University of Queensland, Brisbane, Queensland, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.. Department of Clinical Haematology and BMT, Royal Melbourne Hospital, Melbourne, Victoria, Australia.. Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Royal Adelaide Hospital, Adelaide, South Australia, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Royal Adelaide Hospital, Adelaide, South Australia, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Faculty of Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Queen Elizabeth Hospital, Adelaide, South Australia, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.. Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, The Alfred Hospital, Melbourne, Victoria, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Royal Hobart Hospital, Hobart, Tasmania, Australia.. Faculty of Health, University of Tasmania, Hobart, Tasmania, Australia..
Department of Haematology, Concord Hospital, Sydney, New South Wales, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Royal Darwin Hospital, Darwin, Northern Territory, Australia..
Department of Haematology, Southern Health, Melbourne, Victoria, Australia.. Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.. Department of Haematology, Royal North Shore Hospital, Sydney, New South Wales, Australia..
Medical and Scientific Advisory Group, Myeloma Australia, Melbourne, Victoria, Australia.. Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.. Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia..
Issue Date: Jan-2017
Citation: Internal medicine journal 2017-01; 47(1): 35-49
Abstract: Waldenström macroglobulinaemia (WM) is an indolent B-cell malignancy characterised by the presence of immunoglobulin M (IgM) paraprotein and bone marrow infiltration by clonal small B lymphocytes, plasmacytoid lymphocytes and plasma cells. The symptoms of WM are protean, often follow an asymptomatic phase and may include complications related to the paraneoplastic effects of IgM paraprotein. The revised 2016 World Health Organization classification includes the MYD88 L265P mutation, which is seen in >90% of cases, within the diagnostic criteria for WM. While treatment of WM has often been considered together with other indolent B cell lymphomas, there are unique aspects of WM management that require specific care. These include the unreliability of IgM and paraprotein measurements in monitoring patients prior to and after treatment, the lack of correlation between disease burden and symptoms and rituximab-induced IgM flare. Moreover, while bendamustine and rituximab has recently been approved for reimbursed frontline use in WM in Australia, other regimens, including ibrutinib- and bortezomib-based treatments, are not funded, requiring tailoring of treatment to the regional regulatory environment. The Medical and Scientific Advisory Group of the Myeloma Foundation Australia has therefore developed clinical practice guidelines with specific recommendations for the work-up and therapy of WM to assist Australian clinicians in the management of this disease.
URI: http://docs.prosentient.com.au/prosentientjspui/handle/1/10310
DOI: 10.1111/imj.13311
Type: Journal Article
Subjects: Waldenström macroglobulinaemia
ibrutinib, bendamustine
lymphoplasmacytic lymphoma
monoclonal gammopathy of undetermined significance
rituximab
Advisory Committees
Antineoplastic Agents
Australia
Bendamustine Hydrochloride
Bone Marrow
Bortezomib
Humans
Immunoglobulin M
Mutation
Myeloid Differentiation Factor 88
Plasma Cells
Practice Guidelines as Topic
Pyrazoles
Pyrimidines
Rituximab
Societies, Medical
Waldenstrom Macroglobulinemia
Appears in Collections:NT Health digital library

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.